- Policy
- $25.5 billion in exports to the health industry
- by Kim, Jung-Ju Dec 14, 2022 05:56am
- Exports of health medicine-related industries this year amounted to $25.5 billion, similar to last year, but the export of medicines such as biosimilars and vaccines was notable. The pharmaceutical sector is expected to surpass $10 billion for the first time next year based on a single item, raising expectations as a next-generation "good son ex
- Company
- Prolia's annual sales are expected to be 100 billion won
- by Kim, Jin-Gu Dec 14, 2022 05:56am
- Amgen's Prolia, which dominated the osteoporosis treatment market, is further strengthening its dominance system. Sales are expected to surpass 100 billion won by the end of this year. Evenity, a generic for Prolia, is also rapidly increasing its sales. It has grown into the second-largest product in the osteoporosis treatment market in less
- Company
- Baxter ranks first in the 70 billion hemostatic market
- by Nho, Byung Chul Dec 13, 2022 06:07am
- In the 70 billion won-shaped hemostatic market, Baxter Floseal is likely to surpass 30 billion won in sales this year, and is expected to rank first for the third consecutive year. According to the drug distribution performance data, Baxter Flossal's sales reached 25.3 billion won and Hyundai Pharmaceutical's Tachosil's sales reached 12.5 bi
- Opinion
- [Reporter’s View] Value of convenience in drug intake
- by Eo, Yun-Ho Dec 13, 2022 06:07am
- Taking the right medicine and taking the daily drug only once every month. This convenience in administration has become a competitivity in the pharmaceutical market. Although this had been more emphasized in the field of chronic diseases in the past, it is being emphasized in the field of anticancer drugs as well. The emergence of one-sh
- Company
- Sales of Actinum series have been sluggish
- by Nho, Byung Chul Dec 13, 2022 06:07am
- The Actinum series, once known as Takeda Pharmaceutical's signature mixed vitamin, is experiencing its biggest sales slump in more than seven years since its launch. According to drug distribution performance data, the performance of the Actinium series last year was 2.3 billion won, down 74% from 8.9 billion won in 2018. Between 2018 and 20
- Policy
- Reimb of Samil·Kukje's rebamipide eye drops adequate
- by Lee, Tak-Sun Dec 13, 2022 06:07am
- Samil Pharmaceutical and Kukje Pharma’s rebamipide eye drop solutions that were developed as a treatment for dry eye were deemed adequate for reimbursement by Korea’s Health Insurance Review and Assessment Service. This is the first achievement made for the drug in 4 months since its approval in June. With the reimbursement adequacy recog
- Policy
- Big Pharma's sale of Old Drug has increased
- by Lee, Tak-Sun Dec 13, 2022 06:07am
- The number of domestic pharmaceutical companies acquiring domestic copyrights of original drugs has been increasing recently. This is a case in which domestic copyrights have also changed as most original developers sold global copyrights as part of restructuring. Jeil announced on the 8th that it will exclusively supply Bonviva and Bonviva p
- Policy
- Will SGLT2 combi benefit expansion eventually not happen?
- by Lee, Tak-Sun Dec 12, 2022 05:48am
- iDiscussions on the expansion of combined benefits between SGLT-2 drugs and other drugs continue to conflict. The government presented a voluntary cut rate to related companies last month to analyze their fiscal impact based on it, which is known to fall short of expectations. As a result, it is expected that it will soon be decided whether to
- Company
- “Tagrisso shows effect as 1st-line in the real world"
- by Dec 12, 2022 05:48am
- AstraZeneca’s 3rd generation EGFR mutation-positive non-small cell lung cancer (NSCLC) treatment ‘Tagrisso (osimertinib)’ has shown consistent effects with the clinical trial results in practice. In the real world, Tagrisso demonstrated excellent treatment effects even in patients with brain metastasis, poor systemic condition, or patients wi
- Company
- Nucala retries insurance benefits for the first time in five
- by Eo, Yun-Ho Dec 12, 2022 05:48am
- Nucala, a respiratory antibody drug, is seeking to register insurance benefits again. According to related industries, GSK Korea recently submitted an application for the salary of Nucala, a severe eosinophilic asthma treatment. It is the first re-challenge in about five years since the non-reimbursed decision of the Drug Benefit Evaluation C
